Post-marketing Surveillance of Children With Chronic Hepatitis C Treated With Intron A (Vial or Pen) and Rebetol (Study P04397)(TERMINATED)

Inclusion Criteria

• •Patients with chronic hepatitis C (serum HCV-RNA-positive)
• •Age 3 to 17 years
• •Treatment-naïve
• •Platelets \>= 100,000/mm\^3
• •Neutrophil counts \>= 1,500/ mm\^3
• •TSH must be within normal limits
• •Hemoglobin \>=12 g/dL (females); \>=13 g/dL (males)
• •Women of childbearing potential must have a routine pregnancy test performed monthly during treatment and for 7 months thereafter. Sexually active female subjects of childbearing potential must be practicing adequate contraception (intrauterine device, oral contraceptives, implanted contraceptives, surgical sterilization, barrier method, or monogamous relationship with a male partner who has had a vasectomy or is using a condom (+ spermicide) during the treatment period and for 7 months after stopping treatment.
• •Sexually active male subjects must be practicing acceptable methods of contraception (vasectomy, use of condom + spermicide, monogamous relationship with a female partner who practices an acceptable method of contraception) during the treatment period and for 7 months after stopping treatment.